環球戰略集團(08007.HK)供股獲2.08億股有效接納及申請
環球戰略集團(08007.HK)公布,於今年8月31日,供股已接獲20份暫定配額通知書項下暫定配額之有效接納,涉及合共1.32億股供股股份,相當於供股提呈發售合共3.65億股供股股份的約36.27%;及已接獲9份額外申請表格項下額外供股股份之有效申請,涉及合共7,527.3萬股供股股份,相當於發售供股股份約20.64%。
公司合共接獲29份涉及合共2.08億股供股股份之有效接納及申請,相當於發售供股股份約56.91%。因此,供股有1.57億股供股股份未獲認購,相當於發售供股股份約43.09%,有關股份已被包銷商促使認購人認購。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.